Canaccord Genuity Raises TMDX Price Target to $142, Boosts Buy Rating

Canaccord Genuity raises TransMedics Group's (TMDX) price target from $129 to $142, a 10.08% increase. The maintained "Buy" rating reflects optimism in the company's performance outlook. Analysts forecast an average target price of $145.75 with a 24.82% upside from the current price. The estimated GF Value in one year is $256.21, suggesting a 119.42% upside.

Canaccord Genuity Group has increased the price target for TransMedics Group, Inc. (NASDAQ:TMDX) from $129 to $142, representing a 10.08% increase. The firm maintains a "Buy" rating, reflecting optimism in the company's performance outlook.

Analysts at Canaccord Genuity Group have raised their price target for TransMedics Group, Inc. (TMDX) from $129 to $142, an increase of 10.08% [1]. This new target price suggests a potential upside of 21.58% from the stock's previous close. The firm's "Buy" rating indicates a positive outlook on the company's future prospects.

The increase in the price target comes amid a series of positive developments for TransMedics Group, Inc. The company recently reported earnings per share (EPS) of $0.70 for the quarter, beating analysts' consensus estimates of $0.29 by $0.41 [1]. Revenue for the quarter was $143.54 million, an increase of 48.2% year-over-year.

Additionally, several institutional investors have increased their stakes in TransMedics Group, Inc. during the first quarter. The New York State Teachers Retirement System lifted its position by 183.2%, acquiring an additional 14,200 shares [1]. Other notable investors include Atlas Capital Advisors Inc., AlphaQuest LLC, and Rakuten Securities Inc., who have also increased their holdings in the company.

The current consensus rating for TransMedics Group, Inc. is "Moderate Buy," with an average target price of $131.56 [1]. The estimated GF Value in one year is $256.21, suggesting a potential upside of 119.42% from the current price. However, it is essential to consider the company's debt-to-equity ratio of 1.92 and the fact that 7.00% of the stock is owned by company insiders.

In summary, Canaccord Genuity Group's increased price target for TransMedics Group, Inc. reflects a positive outlook on the company's performance. However, investors should conduct their due diligence and consider the company's financial health and market conditions before making investment decisions.

References:
[1] https://www.marketbeat.com/instant-alerts/filing-new-york-state-teachers-retirement-system-acquires-14200-shares-of-transmedics-group-inc-nasdaqtmdx-2025-07-10/
[2] https://www.marketbeat.com/instant-alerts/transmedics-group-nasdaqtmdx-given-new-14200-price-target-at-canaccord-genuity-group-2025-07-15/